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ABSTRACT
Background. Less than 3% of older patients with cancer
are enrolled in clinical trials. To reverse this underrepre-
sentation, we compared older patients enrolled with
older-patient-speciﬁc trials, deﬁned as those designed
for older patients with cancer, with those enrolled in
age-unspeciﬁed trials.
Materials and Methods. We focused on individual patient
data from those ≥65 years (younger patients excluded) and
included all Alliance phase III adjuvant breast cancer trials
from 1985–2012.
Results. Among 2,277 patients, 1,014 had been enrolled to
older-patient-speciﬁc and 1,263 to age-unspeciﬁed trials. The
median age (range) in the older-patient-speciﬁc trials was
72 (65–89) years compared with 68 (65–84) years in the
cohort of older patients in age-unspeciﬁed trials; p < .0001.
A greater percentage of patients 75 years or older had
enrolled in older-patient-speciﬁc trials compared with the
cohort of age-unspeciﬁed trials: 26% versus 6% (p < .0001).
Median overall survival (OS) was 12.8 years (95% conﬁdence
interval [CI], 11.9–13.7) and 13.5 years (95% CI, 12.9–14.1) for
older-patient-speciﬁc and age-unspeciﬁed trials, respectively.
OS was comparable (hazard ratio [HR], 1.08; 95% CI,
0.92–1.28; p = .34; referent: age-unspeciﬁed trials), after
adjusting for age, estrogen receptor status, tumor size, and
lymph node status. Similar ﬁndings were reached for recur-
rence-free survival. A lower rate of grade 3–5 adverse events
(hematologic and nonhematologic) was reported in older-
patient-speciﬁc trials (43% vs. 58%; p < .0001). Sensitivity
analysis with chemotherapy only trials and subset analysis,
adjusted for performance score, yielded similar OS results.
Conclusion. Older-patient-speciﬁc trials appear to address
this underrepresentation of older patients with ostensibly
comparable outcomes. Clinical trial identiﬁcation numbers.
NCT00003088 (CALGB 9741); NCT00024102 (CALGB 49907);
NCT00068601 (CALGB 40401); NCT00005970 (NCCTG N9831)
The Oncologist 2019;24:e284–e291
Implications for Practice: This work underscores the importance of clinical trials that focus on the recruitment of older
patients with cancer.
INTRODUCTION
Less than 3% of older patients with cancer are enrolled in can-
cer clinical trials, and, for drug registration trials, less than 10%
of patients are 75 years of age or older [1]. Moreover, trends
in recruitment of older patients to large national cancer trials
show, at best, only modest improvements [2–5]. This predica-
ment of poor accrual of older patients with cancer to cancer
clinical trials creates unﬁlled gaps in our knowledge of
how best to provide cancer care to an increasingly growing
population. For breast cancer, close to half of all malignant
diagnoses occur in older women, and close to half of cancer
deaths also occur in older women [6]. Indeed, the incidence
of breast cancer, as well as other malignancies, is expected to
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increase further as the population ages and as life expec-
tancy continues to lengthen.
A variety of efforts—such as high-level policy statements,
health care provider education, legislative changes to cover reim-
bursement, and others—are underway to improve rates of
accrual of older patients to cancer clinical trials [7–9]. One such
effort consists of the purposeful design of clinical trials for older
patients, herein referred to as older-patient-speciﬁc trials, with
the goal of tailoring therapeutic interventions to address func-
tional, biological, or other factors germane to older patients with
cancer [10]. At times, however, such efforts have been met with
controversy. In a commentary entitled “Do we protect or discrimi-
nate? Representation of senior adults in clinical trials,” Kázmierska
points out that less aggressive treatment of older patients with
cancer can yields inferior outcomes but also acknowledges
heterogeneity among older patients and the fact that broad-
based enrollment of older patients provides an essential
source of knowledge that enables oncology health care pro-
viders to render the best possible cancer care [11].
In this context, the current study was undertaken to
assess whether the development and conduct of older-
patient-speciﬁc trials is justiﬁed. The objective was to com-
pare characteristics and outcomes of patients enrolled on
older-patient-speciﬁc trials, deﬁned as those purposely
designed for older patients with cancer, with older patients
enrolled on age-unspeciﬁed trials. Importantly, to achieve
this objective, the current study relied on individual patient
data from prospective trials conducted within a nationally-
funded, multi-institutional organization.
MATERIALS AND METHODS
Overview
The Mayo Clinic institutional review board (IRB) approved
this pooled analysis, which used individual patient data
from all phase III adjuvant breast cancer trials conducted
from 1985 to 2012 within Cancer and Leukemia Group B
and North Central Cancer Treatment Group (both now part
of the Alliance for Clinical Trials in Oncology) [12–19].
A deliberate decision was made to focus only on postoper-
ative, adjuvant clinical trials to circumvent the confounding
effects of more advanced disease on overall survival (OS).
Each patient had signed an IRB-approved, protocol-speciﬁc
informed consent document, in accordance with federal
and institutional guidelines.
Description of Trials and Patients
Older-patient-speciﬁc trials were those that restricted enroll-
ment to older patients (Table 1). Age-unspeciﬁed trials were
those that enrolled patients 18 years of age or older (Table 1).
The decision to focus exclusively on older patients appeared
advantageous for answering the primary question of whether
older-patient-speciﬁc trials are able to address this underrep-
resentation of older patients on cancer clinical trials. Further-
more, the choice of the age cutoff point of 65 years (patients
younger than 65 years from age-unspeciﬁed trials were
excluded from all analyses) is based on precedent from previ-
ous studies and on Medicare eligibility criteria.
Selection of Patient Characteristics and Endpoints
We sought to compare the following demographic variables
based on trial types: patient age at trial entry, patient race
and ethnicity, tumor size, number of positive lymph nodes,
and estrogen receptor (ER) status and progesterone receptor
(PR) status. Because only two trials reported on Eastern
Cooperative Oncology Group (ECOG) performance score, a
subgroup analysis was used to compare this variable-based
on trial type [12, 14, 15].
For OS, the event was death from any cause, and the
time to event was deﬁned as the interval from randomiza-
tion within each trial until death or last follow-up, which-
ever occurred ﬁrst. The event for recurrence-free survival
(RFS) was cancer recurrence or death, whichever occurred
ﬁrst. The time to RFS was deﬁned as the interval from ran-
domization to cancer recurrence, death, or last follow-up.
For both OS and RFS, patients lost to follow-up were cen-
sored at the time of their last visit. Finally, we compared
the frequency of adverse events by grade.
Statistical Methods
Baseline characteristics were summarized for each type by
mean (SD) and median (range) for continuous variables and
by frequency (percentage) for categorical variables. Patient
Table 1. Trials included in the pooled analysis
Trial Trial type Dates of accrual Treatment arms
CALGB 49907 [11] Older-patient-speciﬁc June 2002–December 2006 Standard therapy vs. capecitabine
NCCTG 89-30-52 [12] Older-patient speciﬁc January 1991–April 1995 Tamoxifen alone vs. tamoxifen combined
with ﬂuoxymesterone
CALGB 40101 [13, 14] Age-unspeciﬁed June 2002–July 2010 Cyclophosphamide and doxorubicin vs. paclitaxel
NCCTG N9831 [15] Age-unspeciﬁed May 2000–April 2005 Sequential vs. concurrent therapy with
doxorubicin, cyclophosphamide paclitaxel
and trastuzumab
CALGB 9741 [16] Age-unspeciﬁed October 1997–March 1999 Sequential vs. concurrent therapy with
doxorubicin, cyclophosphamide and paclitaxel
CALGB 9344 [17] Age-unspeciﬁed May 1994–April 1997 4 cycles of doxorubicin/cyclophosphamide vs.
doxorubicin/cyclophosphamide followed by
4 cycles of paclitaxel
CALGB 8541 [18] Age-unspeciﬁed January 1985–March 1991 Low vs. standard vs. high-dose
cyclophosphamide/doxorubicin/5-ﬂuorouracil
Abbreviations: CALGB, Cancer and Leukemia Group B; NCCTG, North Central Cancer Treatment Group.
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characteristics were compared between trial type with the
Kruskal-Wallis test for continuous variables and Pearson’s
chi-square test for categorical variables.
OS and RFS were summarized by trial type with the
Kaplan-Meier estimator. OS and RFS were compared
between trial type with multivariable Cox proportional
hazard regression models. The Cox models included trial
type (older-patient-speciﬁc vs. age-unspeciﬁed) as the main
effect. Other covariates considered in the Cox models
included age (<70 vs. 70–75 vs. >75 years), ER status (negative
vs. positive), tumor size (diameter <3 cm vs. ≥3 cm), positive
lymph nodes (0 vs. 1–3 vs. 4–9 vs. 10+), ethnicity, and ECOG
performance status (0 vs. 1–2). A stepwise procedure was
used to select the covariates in the ﬁnal models with trial type
(the main effect) included in all steps of the model selection.
Variables that retained statistical signiﬁcance at the two-sided
type I error of 0.05 were included in the ﬁnal models. The pro-
portional hazards assumption was tested for all variables in
the Cox model. In a subgroup analysis that focused only on tri-
als that captured performance score, adjusted survival curves
based on the ﬁnal Cox model were created. Adverse events
were summarized by maximum grade level separately by trial
type with frequencies and percentages and were compared
between trial types with the Pearson’s chi-square test.
A deliberate decision was made to not characterize non-
hematologic adverse events based on trial type in detail, as
adverse event data from trial to trial were difﬁcult to harmo-
nize with accuracy.
Data collection and statistical analyses were conducted
by the Alliance Statistics and Data Center. All analyses were
Table 2. Characteristics of cohorts in older-patient-speciﬁc and age-unspeciﬁed trials
Characteristics
Older-patient-speciﬁc trials
(n = 1,014), n (%)
Age-unspeciﬁed trials
(n = 1,263), n (%) p value
Median age at trial entry (range), yr 72 (65–89) 68 (65–84) <.0001
Age at enrollment (percentage of cohort)
≥70 years 567 (56) 369 (30) <.0001
≥75 years 260 (26) 77 (6) <.0001
ECOG performancea <.0001
0 457 (72) 394 (84)
1 161 (25) 74 (16)
2 15 (2) 0
Missing 381 795
Hispanic .89
No 908 (97) 1,172 (97)
Yes 30 (3) 40 (3)
Missing 76 51
Tumor size, cm .80
<3 707 (70) 870 (69)
≥3 305 (30) 384 (31)
Missing 2 9
Number of positive lymph nodesb <.0001
0 367 (37) 324 (28)
1–3 471 (47) 423 (36)
4–9 124 (12) 266 (23)
10+ 44 (4) 163 (14)
Missing 8 87
Estrogen receptor statusa .06
Positive 418 (66) 774 (62)
Negative 214 (34) 481 (38)
Missing 382 8
Progesterone receptor statusa .14
Positive 333 (53) 707 (57)
Negative 297 (47) 545 (43)
Missing 384 11
aPerformance score was not available for trials NCCTG 89-30-52, NCCTG 9831, CALGB 9741, CALGB 9344, or CALGB 8541, leaving 381 and 795
patients with missing data in older-age-speciﬁc and age-unspeciﬁed trials, respectively. Missing data with respect to ER status also occurred in
382 patients in older-patient-speciﬁc trials and 8 patients in age-unspeciﬁed trials and with respect to PR in 384 older age-speciﬁc trials and 11
age-unspeciﬁed trials.
bNumbers in parentheses refer to percentages within the cohort and may not sum to 100% because of rounding.
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performed with SAS Version 9.4 software (SAS Institute
Inc., Cary, NC). Data quality was ensured by review of data
by the Alliance Statistics and Data Center and by the study
chairperson following Alliance policies.
RESULTS
Baseline Characteristics
A total of 2,277 patients were included in this pooled analysis
of individual patient data; 1,014 patients were from older-
patient-speciﬁc trials, and 1,263 were from age-unspeciﬁed
trials (Table 2). The median age of older-patient-speciﬁc trials
was 72 (range, 65–89) years versus 68 (range, 65–84) years
for the older cohort in the age-unspeciﬁed trials (p < .0001).
Among older-patient-speciﬁc trials, 26% (260/1014) of
patients were older than 75 years of age at trial entry,
whereas only 6% (77/1263) in age-unspeciﬁed trials were
within this older age group (p < .0001).
As noted, performance score data were available for
only one older-patient-speciﬁc trial (CALGB 49907; n = 633)
and one age-unspeciﬁed trial (CALGB 40401; n = 468).
Figure 1. Survival outcomes based on trial type. Median overall survival was comparable based on trial type: 12.8 years (95% CI,
11.9–13.7) and 13.5 years (95% CI, 12.9–14.1) in older-patient-speciﬁc trials and age-unspeciﬁed trials, respectively. Similarly, median
recurrence-free survival was comparable based on trial type: 11.3 years (95% CI, 10.6–12.2) versus 12.7 years (95% CI, 11.9–13.6).
Abbreviation: CI, conﬁdence interval.
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Among patients with reported ECOG performance score,
72% (457/633) of patients in older-patient-speciﬁc trials had
a performance score of zero compared with 84% (394/468)
in age-unspeciﬁed trials (p < .0001). Other baseline charac-
teristics appear in Table 2.
Survival
Median OS was 12.8 years (95% conﬁdence interval [CI],
11.9–13.7) and 13.5 years (95% CI, 12.9–14.1) in older-
patient-speciﬁc trials and age-unspeciﬁed trials, respectively
(Fig. 1). OS was comparable (hazard ratio [HR], 1.08; 95% CI,
0. 92–1. 28; p = .34; referent: age-unspeciﬁed trials), after
adjusting for age, estrogen receptor status, tumor size, and
lymph node status. (Table 3, Fig. 1).
Median RFS was 11.3 years (95% CI, 10.6–12.2 years) in
older-patient-speciﬁc trials versus 12.7 years (95% CI, 11.9–
13.6 years) in age-unspeciﬁed trials. RFS was comparable
between trial type (HR, 1.10; 95% CI, 0.94–1.28; p = .24; ref-
erent: older-patient-speciﬁc trials), after adjusting for patient
age, ethnicity, and ER status. (Table 3, Fig. 1).
Although only two trials captured patient performance
scores, and although older patients had worse scores, a
two-trial subgroup that included performance score into
the model showed comparable OS based on trial type after
adjusting for performance scores (Fig. 2) [11, 13, 14]. Another
subgroup analysis which excluded the older-patient-speciﬁc
trial that tested hormonal therapy yielded similar ﬁndings
(data not shown).
Adverse Events
Maximum grade 3–5 adverse events (which included both
hematologic and nonhematologic adverse events) were
reported in 43% (405/941) of patients older-patient-speciﬁc
trials compared with 58% (630/1086) in age-unspeciﬁed trial.
Speciﬁcally, a higher rate of grade 4 was reported in older-
patient-speciﬁc trial (p < .0001; Table 4). A lower rate of
grade 3–5 nonhematologic adverse events were reported in
older-patient-speciﬁc trials (34% vs. 48%) and a lower rate of
grade 3–5 hematologic adverse events (19% versus 31%;
Table 4).
DISCUSSION AND CONCLUSION
This pooled analysis of 2,277 older patients with breast can-
cer shows that older-patient-speciﬁc trials capture a much
older group of patients with cancer, many of whom other-
wise might never have entered a clinical trial. Importantly,
we relied on individual patient data, thus making this study
particularly robust. To recapitulate ﬁndings, 26% of patients
enrolled in older-patient-speciﬁc trials were 75 years of age
or older in contrast to less than 10% in the cohort of age-
unspeciﬁed trials and in cancer registration trials in general
[1]. By testing gentler cancer treatment, older-patient-
speciﬁc trials appear to render care to patients with ostensibly
little compromise in outcomes. The current study suggests that
well-designed older-patient-speciﬁc trials serve an important
role in accruing older patients—and potentially also those with
poor performance scores—to clinical trials and in deﬁning the
standard of cancer care for older patients with cancer. Ostensi-
bly, neither overly protective nor discriminatory, older-patient-
speciﬁc trials appear to accomplish the goals of any other
well-designed clinical trial.
The ﬁndings from the current study are in keeping with a
previous pooled analysis, which drew similar conclusions in
patients with metastatic non-small cell lung cancer [20]. That
earlier study also revealed no statistical differences in sur-
vival outcomes between older patients enrolled in older-
patient-speciﬁc trials and those enrolled in age-unspeciﬁed
trials; adverse event proﬁles across trial types were also rela-
tively comparable. Although this pooled analysis of adjuvant
breast cancer trials is far more robust, these earlier ﬁndings
add credence and underscore a consistent message that
older-patient-speciﬁc trials appear to serve an important role
Table 3. Multivariate analysis of overall survival (OS) and
recurrence-free survival (RFS)
Variablea
Hazard ratio,
(95% conﬁdence
interval) p value
OS
Trial type (referent
age-unspeciﬁed)
1.08 (0.92–1.28) .34
Age, yr <.0001b
<70 1
70–75 1.29 (1.12–1.49) .0004
>75 2.35(1.98–2.78) <.0001
Tumor size, cm
<3 1
≥3 1.38 (1.21–1.57) <.0001
Number of positive
lymph nodesc
<.0001b
0 1
1–3 1.40 (1.19–1.65) <.0001
4–9 2.04 (1.69–2.46) <.0001
10+ 2.75 (2.21–3.45) <.0001
Estrogen receptor statusb
Negative 1
Positive 0.81 (0.69–0.94) .0045
RFSd
Trial type (referent
age-unspeciﬁed)
1.10 (0.94–1.29) .24
Age <.0001b
<70 years 1
70–75 years 1.23 (1.07–1.41) .0028
>75 years 2.04 (1.73–2.41) <.0001
Hispanic
No 1
Yes 1.67 (1.15–2.43) .0072
Estrogen receptor status
Negative 1
Positive 0.80 (0.70–0.93) .0025
aSelect variables are shown.
bOverall p value.
cMissing data (n = 88 for lymph node status and n = 384 for estro-
gen receptor status) were included in the model.
dModel was stratiﬁed by tumor size and number of positive nodes.
Abbreviations: OS, overall survival; RFS, regression-free survival.
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in helping us understand how best to render cancer treat-
ment to older patients with cancer.
With respect to trial design, it should be emphasized that
older-patient-speciﬁc trials merit the same careful thought
and planning with respect to drug doses and other treatment
conditions as any other cancer clinical trial. Previous studies
have shown that undertreating older patients with cancer
can, in fact, give rise to suboptimal outcomes. For example,
Bouchard and others examined over 30 studies on the
undertreatment of breast cancer in older patients and con-
cluded that “undertreatment is a well-documented phenom-
enon responsible for preventable cancer deaths” [21]. In
concert with such observations, the study from Muss and
others, as integrated into the current pooled analysis, dem-
onstrated that adjuvant capecitabine—a gentler, oral chemo-
therapy regimen that patients often prefer and that is
effective in metastatic breast cancer—was clearly inferior
when compared with standard adjuvant chemotherapy (either
Figure 2. Subgroup analysis of overall survival based on trial type but with adjustment for performance score. In a subgroup analysis
that included only trials that captured baseline performance score, older-patient speciﬁc trials appeared initially to inferior survival
(top set of curves): 12.5 years (95% CI, 11.5–13.7 years) in older-patient-speciﬁc trials and median not reached for age-unspeciﬁed
trials (the longest follow-up was 14 years), but after adjustment for performance score, overall survival curves show comparable
outcomes (bottom set of curves): 13.7 years (95% CI, 13.1 years–not reached) in older-patient-speciﬁc trials and median not
reached for age-unspeciﬁed trials (again, the longest follow-up was 14 years).
Abbreviations: CI, conﬁdence interval; NE, not estimable.
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cyclophosphamide, methotrexate, and ﬂuorouracil or cyclo-
phosphamide plus doxorubicin) [12]. Adjuvant capecitabine
resulted in higher rates of cancer recurrence and death. Thus,
older-patient-speciﬁc trials should not only be testing a
hypothesis that favors a less aggressive therapeutic approach.
Rather, building on the concept of equipoise, such trials can be
aimed at deﬁning an optimal treatment—whether more
aggressive or less aggressive than the current standard—and
contribute to an otherwise sparse evidence base for older
patients with cancer.
This pooled analysis has limitations. First, as is often the
case in such analyses, we were forced to contend with trial
heterogeneity and missing data. To address heterogeneity, we
adjusted for multiple variables in our Cox models. Performance
scores were available from only two trials—one older-patient-
speciﬁc trial and one age-unspeciﬁed trial. To overcome these
shortcomings, we conducted a subgroup analyses with our lim-
ited data on performance score only to conﬁrm our main OS
ﬁndings, as stated above, in multivariate analyses. The ﬁndings
from this subgroup analysis also underscore the importance of
including broader eligibility criteria in age-unspeciﬁed trials.
Second, with respect to adverse event data, we were unable
to provide the desired granularity on what types of non-
hematological adverse events were more commonly observed
in older-patient speciﬁc trials. The limitations entailed in har-
monizing adverse event data across trials made it impossible
to acquire the desired degree of detail with accuracy. Future
studies might focus on understanding age-based differences in
speciﬁc adverse events. Third, an important caveat is that we
focused only on clinical trial data. It is well accepted that clini-
cal trial enrollment entails a selection process that has the
potential to bias any and all trial results toward conclusions
perhaps relevant to only the ﬁttest of older patients with can-
cer. Importantly, in view of the types of information gathered
during the conduct of these trials, we are unable to comment
on baseline morbidity and differences based on trial type.
Nonetheless, the fact that older-patient-speciﬁc trials appear
to be successful in enrolling a much older patient cohort with
poorer performance status suggests that these trials may cap-
ture patients more representative of the general population of
older patients with cancer. Hence, these trials should be
viewed as an important ﬁrst step in ﬁlling knowledge gaps
for how best to provide cancer care to an increasingly grow-
ing population of patients with cancer.
Finally, when examining the dates of enrollment of older-
patient-speciﬁc trials and age-unspeciﬁed trials, it appears
that older-patient-speciﬁc and age-unspeciﬁed trials heavily
overlap. Yet all the studies in this pooled analysis were able
to complete their accrual and provide important ﬁndings on
the role of adjuvant therapy in patients with breast cancer. In
essence, the data presented here also suggest that these two
different trial types can successfully coexist. In summary, our
results suggest the value of dedicating clinical trials to older
patients, not only to answer therapeutic questions but also
to ascertain the power to assess other endpoints relevant to
older patients with cancer.
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Table 4. Adverse events
Maximum grade
adverse events
Older-patient-speciﬁc
trials (n = 941),
frequency (%)
Age-unspeciﬁed
trials (n = 1,086),
frequency (%) p valuea
0–1 268 (28) 282 (26)
2 268 (28) 174 (16)
3 280 (30) 291 (27)
4 116 (12) 332 (31)
5 9 (1) 7 (1)
Hematologicb grade 3 or worse 174 (19) 341 (31)
Nonhematologicb grade 3 or worse 316 (34) 519 (48)
aOverall comparison between groups: p < .0001.
bThe main adverse event analysis focused on all grade adverse events; hematologic and nonhematologic events are therefore reported
descriptively.
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